Stock Research for DRRX

DRRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

DRRX Stock Chart & Research Data

The DRRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DRRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


DRRX Due diligence Resources & Stock Charts

The DRRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DRRX Detailed Price Forecast - CNN Money CNN View DRRX Detailed Summary - Google Finance
Yahoo View DRRX Detailed Summary - Yahoo! Finance Zacks View DRRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View DRRX Trends & Analysis - Trade-Ideas Barrons View DRRX Major Holders - Barrons
NASDAQ View DRRX Call Transcripts - NASDAQ Seeking View DRRX Breaking News & Analysis - Seeking Alpha
Spotlight View DRRX Annual Report - CompanySpotlight.com OTC Report View DRRX OTC Short Report - OTCShortReport.com
TradeKing View DRRX Fundamentals - TradeKing Charts View DRRX SEC Filings - Bar Chart
WSJ View Historical Prices for DRRX - The WSJ Morningstar View Performance/Total Return for DRRX - Morningstar
MarketWatch View the Analyst Estimates for DRRX - MarketWatch CNBC View the Earnings History for DRRX - CNBC
StockMarketWatch View the DRRX Earnings - StockMarketWatch MacroAxis View DRRX Buy or Sell Recommendations - MacroAxis
Bullish View the DRRX Bullish Patterns - American Bulls Short Pains View DRRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View DRRX Stock Mentions - StockTwits PennyStocks View DRRX Stock Mentions - PennyStockTweets
Twitter View DRRX Stock Mentions - Twitter Invest Hub View DRRX Investment Forum News - Investor Hub
Yahoo View DRRX Stock Mentions - Yahoo! Message Board Seeking Alpha View DRRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for DRRX - SECform4.com Insider Cow View Insider Transactions for DRRX - Insider Cow
CNBC View DRRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DRRX - OTC Markets
Yahoo View Insider Transactions for DRRX - Yahoo! Finance NASDAQ View Institutional Holdings for DRRX - NASDAQ


Stock Charts

FinViz View DRRX Stock Insight & Charts - FinViz.com StockCharts View DRRX Investment Charts - StockCharts.com
BarChart View DRRX Stock Overview & Charts - BarChart Trading View View DRRX User Generated Charts - Trading View




Latest Financial News for DRRX


Is DURECT Corporation’s (NASDAQ:DRRX) Balance Sheet Strong Enough To Weather A Storm?
Posted on Wednesday September 19, 2018

DURECT Corporation (NASDAQ:DRRX) is a small-cap stock with a market capitalization of US$179.8m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...


DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan
Posted on Tuesday September 18, 2018

- ORADUR®-Methylphenidate ER now called Methydur Sustained Release Capsules in Taiwan - Developed by Orient Pharma under a license to the ORADUR® technology from DURECT CUPERTINO, Calif. , Sept. 18, 2018 ...


DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
Posted on Thursday August 30, 2018

On September 26, 2017, DURECT entered into a patent purchase agreement whereby DURECT assigned to Indivior UK Limited, an affiliate of Indivior PLC, certain patents that may provide further intellectual property protection for PERSERIS. In consideration for such assignment, Indivior made an upfront non-refundable payment to DURECT of $12.5 million and also agreed to make an additional $5 million payment to DURECT contingent upon NDA approval of PERSERIS, which occurred in July 2018.  Under the agreement, DURECT is also entitled to receive quarterly earn-out payments that are based on a single digit percentage of U.S. net sales for certain products covered by the assigned patent rights, including PERSERIS.


DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Posted on Monday August 27, 2018

CUPERTINO, Calif. , Aug. 27, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, will be presenting at the 20 th Annual Rodman & Renshaw Global ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.